Journal Article Summary
The article reviews the relationship between combined oral contraceptives (COCs) and the risk of venous thromboembolism (VTE), a serious condition where blood clots form in veins. This topic is significant because millions of women worldwide use COCs for contraception, and even a small increase in VTE risk can impact many lives. The authors discuss historical data showing that COCs have been linked to increased VTE risk since their introduction, emphasizing the need for effective strategies to mitigate this risk.
The authors analyzed various studies and historical data to evaluate how changes in COC formulations have influenced VTE risk. They found that the estrogen dosage in COCs is a major factor contributing to VTE risk, leading to a reduction in estrogen levels in newer formulations. Additionally, the introduction of new progestins has altered the risk profile, with some newer formulations showing lower impacts on coagulation compared to older ones. The review suggests that a more personalized approach, including screening for hereditary thrombophilia, could help healthcare providers prescribe safer contraceptive options.
Despite the insights provided, the article acknowledges limitations, including the variability in study results and the challenges in identifying women at higher risk for VTE. It highlights the importance of discussing individual risk factors with healthcare professionals before starting COCs, as many women may not be aware of their potential risk for thrombosis. Patients are encouraged to engage in conversations about their health history and any concerns regarding contraceptive options to ensure they receive the most appropriate and safe method for their needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Morimont Laure, Haguet Hélène, Dogné Jean-Michel, Gaspard Ulysse, Douxfils Jonathan. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in Endocrinology 2021. DOI: 10.3389/fendo.2021.769187. PMID: 34956081. PMCID: PMC8697849.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
